Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-β in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody

References

Page 1

	Year	Citations
A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone Steven A. Rosenberg, Michael T. Lotze, Linda Muul, New England Journal of Medicine Lymphoid NeoplasiaAdvanced CancerCancer ImmunosurveillanceLak CellsProgress Report	1987	2.8K
Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer Steven A. Rosenberg, Michael T. Lotze, Linda Muul, New England Journal of Medicine	1985	2.6K
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. Elizabeth A. Grimm, A Mazumder, H Z Zhang, The Journal of Experimental Medicine ImmunologyImmunologic MechanismImmune SystemImmunotherapyNatural Killer Cells	1982	2.2K
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Michael T. Lotze, Elizabeth A. Grimm, Amitabha Mazumder, PubMed Lymphoid NeoplasiaSelective LysisCancer ImmunosurveillanceMedicineImmunology	1981	523
Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. Gerald Ranges, I S Figari, Terje Espevik, The Journal of Experimental Medicine Lymphocyte DevelopmentT-regulatory CellImmunologyCell DeathPathology	1987	494
Lymphokine-activated killer cells. Analysis of progenitors and effectors. John R. Ortaldo, Anna Mason, R Overton The Journal of Experimental Medicine Lymphocyte DevelopmentAdaptive Immune SystemImmune RegulationImmunologyImmunologic Mechanism	1986	398
Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. René Lafrenière, Steven A. Rosenberg PubMed Lak CellsImmunologySuccessful ImmunotherapyRecombinant Interleukin 2Immunologic Mechanism	1985	380
Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. A Mazumder, S A Rosenberg The Journal of Experimental Medicine Lak CellsImmunologySuccessful ImmunotherapyImmunologic MechanismImmunotherapy	1984	371
Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Laurie B. Owen‐Schaub, Jordan U. Gutterman, Elizabeth A. Grimm PubMed ImmunologyCell DeathPathologyImmunologic MechanismIl-2 Concentration	1988	176
Transforming growth factor- <i>beta</i> 1 (TGF- <i>beta</i> 1) and recombinant human tumor necrosis factor- <i>alpha</i> reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF- <i>beta</i> 1 and TGF- <i>beta</i> 2, and recombinant human TGF- <i>beta</i> 1. Terje Espevik, I S Figari, Gerald Ranges, The Journal of Immunology	1988	167

Page 1